

Shabnam Jaffer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2319549/publications.pdf>

Version: 2024-02-01

32
papers

456
citations

840776

11
h-index

713466

21
g-index

32
all docs

32
docs citations

32
times ranked

597
citing authors

#	ARTICLE	IF	CITATIONS
1	Excision is indicated for intraductal papilloma of the breast diagnosed on core needle biopsy. <i>Cancer</i> , 2009, 115, 2837-2843.	4.1	95
2	Neurothekeoma and Plexiform Fibrohistiocytic Tumor. <i>American Journal of Surgical Pathology</i> , 2009, 33, 905-913.	3.7	63
3	Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy. <i>JAMA Oncology</i> , 2017, 3, 36.	7.1	57
4	Immunohistochemical detection of antiapoptotic protein X-linked inhibitor of apoptosis in mammary carcinoma. <i>Human Pathology</i> , 2007, 38, 864-870.	2.0	37
5	Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients. <i>International Journal of Breast Cancer</i> , 2017, 2017, 1-6.	1.2	35
6	Beyond Hematoxylin and Eosin—The Role of Immunohistochemistry in Surgical Pathology. <i>Cancer Investigation</i> , 2004, 22, 445-465.	1.3	34
7	Mesenteric Paraganglioma. <i>Archives of Pathology and Laboratory Medicine</i> , 2002, 126, 362-364.	2.5	26
8	High endogenous CCL2 expression promotes the aggressive phenotype of human inflammatory breast cancer. <i>Nature Communications</i> , 2021, 12, 6889.	12.8	25
9	Invasive mucinous carcinoma of the breast and response patterns after neoadjuvant chemotherapy (NAC). <i>Histopathology</i> , 2018, 72, 965-973.	2.9	22
10	Characteristics of Breast Carcinoma Cases With False-Negative Sentinel Lymph Nodes. <i>Clinical Breast Cancer</i> , 2014, 14, 280-284.	2.4	13
11	Cellular fibroadenoma on Core needle biopsy: management recommendations for the radiologist. <i>Clinical Imaging</i> , 2016, 40, 587-590.	1.5	12
12	Cytologic Findings of Spindle Cell Ductal Carcinoma in Situ of the Breast. <i>Acta Cytologica</i> , 2005, 49, 323-326.	1.3	7
13	Response in breast vs axilla after neoadjuvant treatment and implications for nonoperative management of invasive breast cancer. <i>Breast Journal</i> , 2021, 27, 120-125.	1.0	6
14	The Impact of 2013 Updated ASCO/CAP HER2 Guidelines on the Diagnosis and Management of Invasive Breast Cancer: A Single-Center Study of 1739 Cases. <i>Clinical Breast Cancer</i> , 2017, 17, 486-492.	2.4	5
15	Not All Ductal Carcinomas In Situ Are Created IDLE (Indolent Lesions of Epithelial Origin). <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 99-104.	2.5	5
16	MRI Features of Free Liquid Silicone in the Transgender Female Breast. <i>Journal of Breast Imaging</i> , 2021, 3, 322-331.	1.3	3
17	Occult Axillary Node Metastases in Breast Cancer are Prognostically Significant. <i>Advances in Anatomic Pathology</i> , 2008, 15, 370-373.	4.3	2
18	Are cytokeratin-positive cells in sentinel lymph nodes of patients with invasive breast carcinomas up to 5Åmm usually insignificant?. <i>Histopathology</i> , 2015, 66, 283-288.	2.9	2

#	ARTICLE	IF	CITATIONS
19	Ultrasound-guided wire localization of focal ductal dilatation in the evaluation and treatment of pathologic nipple discharge. <i>Breast Journal</i> , 2018, 24, 356-359.	1.0	2
20	Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution. <i>Cancer Reports</i> , 2022, 5, e1481.	1.4	2
21	Application of RSclin to guide treatment recommendations for premenopausal patients with early-stage hormone-positive breast cancer and intermediate risk oncotype recurrence scores.. <i>Journal of Clinical Oncology</i> , 2021, 39, e12511-e12511.	1.6	1
22	Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and >31. <i>Oncology</i> , 2021, 99, 699-702.	1.9	1
23	A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1103-TPS1103.	1.6	1
24	Measuring Invasive Breast Carcinoma on Core Biopsy: Is it Necessary?: An Analysis of Ultrasound, Mammotome, and Magnetic Resonance Imaging-Guided Core Biopsies. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1432-1437.	2.5	0
25	Abstract PS6-27: Secondary invasive breast events (SIBE) among patients with oncotype DX recurrence scores (RS) 26-30 and >31: Results from a large oncotype database. , 2021, , .		0
26	Trends in use of ovarian suppression (OS) for premenopausal patients with early-stage hormone positive breast cancer and Intermediate Risk (IR) Oncotype Recurrence Scores (RS) from 2006-2020: A retrospective database analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, e12522-e12522.	1.6	0
27	Tolerance of aromatase inhibitors in post-menopausal patients with early-stage hormone receptor positive (HR+) breast cancer: A real-world retrospective analysis in a large oncotype database.. <i>Journal of Clinical Oncology</i> , 2021, 39, e12532-e12532.	1.6	0
28	Oncotype recurrence score (RS) and discordance in patients with secondary invasive breast events (SIBE).. <i>Journal of Clinical Oncology</i> , 2019, 37, e12016-e12016.	1.6	0
29	Stratification of oncotype (ODX) Recurrence Score (RS) by Breast Cancer Index (BCI) and its relation to discordance.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12025-e12025.	1.6	0
30	Mastectomy or Margin Re-excision? A Nomogram for Close/Positive Margins After Lumpectomy for DCIS. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
31	ASO Visual Abstract: Mastectomy or Margin Reexcision? A Nomogram for Close/Positive Margins after Lumpectomy for DCIS. <i>Annals of Surgical Oncology</i> , 2022, 29, 3749.	1.5	0
32	Correlation of Ki67 working group prognostic risk categories with oncotype DX recurrence score (RS) in early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 553-553.	1.6	0